DMAC | DiaMedica Therapeutics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.75 - 6.41
52 Week Range	2.1400 - 6.41
Beta	1.47
Implied Volatility	374.35%
IV Rank	57.43%
Day's Volume	216,386
Average Volume	82,842
Shares Outstanding	42,760,600
Market Cap	274,095,446
Sector	Healthcare
Industry	Biotechnology
IPO Date	2012-08-03

Valuation
Profitability
Growth
Health
P/E Ratio	-11.45
Forward P/E Ratio	N/A
EPS	-0.56
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	18
Country	USA
Website	DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC's peers: CLLS, MIST, MCRB, IKT, ONCY, SCPH, LIFE, LYRA, CNTA, IOVA, XFOR, GRTX, TERN, DAWN, HOOK, DYAI, GALT, MNPR, RVNC, SAGE, XCUR, IMNN

*Chart delayed

Analyzing fundamentals for DMAC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see DMAC Fundamentals page.

Watching at DMAC technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on DMAC Technicals page.